Page last updated: 2024-09-03

imatinib mesylate and Endothelioma, Lymphatic

imatinib mesylate has been researched along with Endothelioma, Lymphatic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fernandes, H; Gruden, JF; Libby, DM; Libby, LJ; Narula, N; Wolf, DJ	1

Other Studies

1 other study(ies) available for imatinib mesylate and Endothelioma, Lymphatic

Article	Year
Imatinib Treatment of Lymphangiomatosis (Generalized Lymphatic Anomaly). Journal of the National Comprehensive Cancer Network : JNCCN, 2016, Volume: 14, Issue:4 Topics: Antineoplastic Agents; Biopsy; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Lymphangioma; Middle Aged; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Retreatment; Tomography, X-Ray Computed; Treatment Outcome	2016

Article

Year

Imatinib Treatment of Lymphangiomatosis (Generalized Lymphatic Anomaly).

Journal of the National Comprehensive Cancer Network : JNCCN, 2016, Volume: 14, Issue:4

Topics: Antineoplastic Agents; Biopsy; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Lymphangioma; Middle Aged; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Retreatment; Tomography, X-Ray Computed; Treatment Outcome

2016